← Eichor
Study identifier: NCT06555419 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

Condition: Muscular Atrophy, Spinal  ·  Sponsor: Biogen

PhasePhase 1
Planned participants58
Who can joinAll sexes, 3 Years to no upper limit
Healthy volunteersNo

About this study

In this PIERRE-PK study, researchers will learn how the body processes nusinersen when it is given through the ThecaFlex DRx™ System, compared to when nusinersen is given by lumbar puncture (LP). The ThecaFlex DRx system is an investigational implantable medical device developed by Alcyone Therapeutics, Inc. It consists of a catheter, which is a flexible tube, connected to a port which is placed under the skin. Alcyone Therapeutics, Inc. has an ongoing study called PIERRE to test the ThecaFlex DRx system. Participants with spinal muscular atrophy (SMA) in the PIERRE study may be enrolled in the PIERRE-PK study. The main objective of the PIERRE-PK study is to learn how the body processes nusinersen when given by the ThecaFlex DRx system compared to a lumbar puncture. The main questions researchers want to answer are: * What is the highest amount of nusinersen found in the blood after dosing? * How much nusinersen is found in the blood over the first 24 hours after dosing? The PIERRE-PK study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 30 days for this study and may overlap with the PIERRE study. * Participants will receive a dose of nusinersen by lumbar puncture. * The ThecaFlex DRx system will be implanted after the lumbar puncture, as part of the PIERRE study. * Participants will receive a dose of nusinersen by the ThecaFlex DRx system, as part of the PIERRE study. * Researchers will tak…

This description comes directly from the study's public registry record.

Talk to the study team

US Biogen Clinical Trial Center  ·  866-633-4636  ·  clinicaltrials@biogen.com

Global Biogen Clinical Trial Center  ·  clinicaltrials@biogen.com

Always discuss trial participation with your own doctor first.

Locations (19)

Children's Hospital of Orange CountyOrange, California, United StatesRecruiting
Stanford University Medical Center | Department of Neurology_Palo AltoPalo Alto, California, United StatesRecruiting
Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Illinois, United StatesRecruiting
Boston Children's HospitalBoston, Massachusetts, United StatesRecruiting
Helen DeVos Children's HospitaGrand Rapids, Michigan, United StatesRecruiting
Milton S. Hershey Medical Center | Pennsylvania State University_HersheyHershey, Pennsylvania, United StatesRecruiting
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania, United StatesRecruiting
Texas Childrens Hospital HoustonHouston, Texas, United StatesRecruiting
Stacey Hall Developmental PediatricsCharlottesville, Virginia, United StatesRecruiting
Children's Hospital of the King's Daughters_NorfolkNorfolk, Virginia, United StatesRecruiting
Hôpital Raymond PoincaréGarches, Hauts De Seine, FranceRecruiting
Universitaetsklinikum EssenEssen, GermanyRecruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06555419